Printer Friendly

Newron on track to seek approval for safinamide in H2 2013.

(SeeNews) - Nov 14, 2012 - Italian drug maker Newron (SWF:NWRN) gave an update today on its submissions plans for safinamide in Parkinson's disease (PD) saying that it is on track to apply for approval in the second half of next year.

The company seeks authorisation of the drug as add-on therapy for the treatment of both early (non-fluctuating) and advanced (fluctuating) patients with idiopathic PD.

Newron said that it has recently met with European health regulators to discuss the data from the preclinical, CMC, and clinical studies to support registration of safinamide. The authorities have agreed with the adequacy of the safinamide programme for preclinical toxicology, CMC, DMPK, and the size of the clinical safety data base that will be part of the submission. The company has also received feedback about the findings of the studies showing statistically significant efficacy of safinamide as add-on therapy in patients receiving a stable dose of a single dopamine agonist in early PD patients and on motor fluctuations in patients with advanced PD on levodopa and other PD treatments.

Safinamide is being co-developed by Newron together with its local partner Zambon Pharma and its Japanese collaborator Meiji Seika Pharma.
COPYRIGHT 2012 AII Data Processing Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:SeeNews Austria
Date:Nov 14, 2012
Previous Article:Kinepolis' number of visitors declines 19.6% Y/Y in Q3 2012.
Next Article:Coso Geothermal gets extension on USD 55m letters of credit.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |